within Pharmacolibrary.Drugs.P_AntiparasiticProductsInsecticidesAndRepellents.P02C_AntinematodalAgents.P02CX03_Moxidectin;

model Moxidectin
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.5,
    Cl = 5.277777777777777e-07,
    adminDuration = 600,
    adminMass = 8 / 1000000,
    adminCount = 1,
    Vd = 0.161,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.002,
    Tlag = 60.0,
    Vdp = 0.332,
    k12 = 2.213888888888889e-07,
    k21 = 2.213888888888889e-07);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Moxidectin</td></tr><tr><td>ATC code:</td><td>P02CX03</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>8</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>161</td><td>L</td></tr>
    <tr><td>clearance:</td><td>1.9</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Moxidectin is a macrocyclic lactone anthelmintic used mainly for the treatment of onchocerciasis (river blindness) caused by Onchocerca volvulus, and is also effective against various gastrointestinal nematodes and ectoparasites in veterinary and human medicine. It is approved for human use in some countries for onchocerciasis and is under investigation for other indications.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult volunteers following a single oral dose.</p><h4>References</h4><ol><li><p>Vanapalli, SR, et al., &amp; McCall, JW (2002). Pharmacokinetics and dose proportionality of oral moxidectin in beagle dogs. <i>Biopharmaceutics &amp; drug disposition</i> 23(7) 263–272. DOI:<a href=\"https://doi.org/10.1002/bdd.313\">10.1002/bdd.313</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/12355577/\">https://pubmed.ncbi.nlm.nih.gov/12355577</a></p></li><li><p>Cripps, J, et al., &amp; Coulson, G (2013). The efficacy of anthelmintic drugs against nematodes infecting free-ranging eastern grey kangaroos, Macropus giganteus. <i>Journal of wildlife diseases</i> 49(3) 535–544. DOI:<a href=\"https://doi.org/10.7589/2012-06-151\">10.7589/2012-06-151</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/23778602/\">https://pubmed.ncbi.nlm.nih.gov/23778602</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.P.P02CX03 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Moxidectin;
